Biostar Pharmaceuticals, Inc.
Other OTCTotal Valuation
Biostar Pharmaceuticals, Inc. carries a market capitalization of 264.00, placing it among publicly traded companies globally.
| Market Cap | 264.00 |
| Enterprise Value | N/A |
Share Statistics
Biostar Pharmaceuticals, Inc. currently has 2.64M shares outstanding.
| Shares Outstanding | 2.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Biostar Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 3.64. The price-to-sales ratio is 10.70, and the price-to-book ratio stands at -0.68.
| PE Ratio | 3.64 |
| PS Ratio | 10.70 |
| PB Ratio | -0.68 |
| P/TBV Ratio | 0.11 |
| P/FCF Ratio | 0.40 |
| P/OCF Ratio | 0.40 |
Financial Position
Biostar Pharmaceuticals, Inc. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.19 |
| Quick Ratio | 0.16 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 19.61 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 2.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -32.52 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.16 |
Taxes
Over the trailing twelve months, Biostar Pharmaceuticals, Inc. has paid 2.65M in income taxes, reflecting an effective tax rate of 73.95.
| Income Tax | 2.65M |
| Effective Tax Rate | 73.95 |
Stock Price Statistics
Biostar Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Biostar Pharmaceuticals, Inc. generated 317,794.00 in revenue and converted that into 934,352.00 in net income, yielding earnings per share of 0.35. EBITDA reached 3.95M, while operating income came in at 2.84M.
| Revenue | 317,794.00 |
| Gross Profit | -36,747.00 |
| Operating Income | 2.84M |
| Pretax Income | 3.59M |
| Net Income | 934,352.00 |
| EBITDA | 3.95M |
| EBIT | 2.84M |
| Earnings Per Share (EPS) | 0.35 |
Balance Sheet
Total book value stands at -4.99M, with working capital of -4.28M providing operational flexibility.
| Cash & Cash Equivalents | 364,973.00 |
| Total Debt | N/A |
| Net Debt | 2.06M |
| Equity (Book Value) | -4.99M |
| Book Value Per Share | -1.89 |
| Working Capital | -4.28M |
Cash Flow
Biostar Pharmaceuticals, Inc. produced 8.59M in operating cash flow over the past twelve months.
| Operating Cash Flow | 8.59M |
| Capital Expenditures | N/A |
| Free Cash Flow | 8.59M |
| FCF Per Share | 3.26 |
Margins
Biostar Pharmaceuticals, Inc. operates with a gross margin of -11.56, reflecting its pricing power and cost economics. The operating margin of 893.30 and net profit margin of 294.01 provide insight into operational efficiency.
| Gross Margin | -11.56 |
| Operating Margin | 893.30 |
| Pretax Margin | 1,128.85 |
| Profit Margin | 294.01 |
| EBITDA Margin | 1,242.26 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -49.74 |
| FCF Yield | 252.42 |
Stock Splits
Biostar Pharmaceuticals, Inc.'s most recent stock split took place on February 5, 2016 with a 7:1 split ratio.
| Last Split Date | 2/5/2016 |
| Split Ratio | 7:1 |
Scores
Biostar Pharmaceuticals, Inc. posts an Altman Z-Score of 0.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.32 |